ANAB vs TRAX
ANAB: AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own clinical-stage pipeline for autoimmune and inflammatory diseases. TRAX: Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.
Side-by-side fundamentals
| Metric | ANAB | TRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $52.61 | $38.17 | |
| Market cap as of 2026-07-23 | $1.6B | $1.3B | |
| Net margin as of 2026-07-23 | -11.5% | n/a | |
| Operating margin as of 2026-07-23 | +17.6% | n/a | |
| ROE as of 2026-07-23 | -13.1% | -57.8% | ANAB higher |
| ROA as of 2026-07-23 | -7.8% | -50.2% | ANAB higher |
| Debt / equity as of 2026-07-23 | 20.69 | 0.00 | TRAX lower |
| Revenue growth (YoY) as of 2026-07-23 | +107.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +183.6% | n/a | |
| Beta as of 2026-07-23 | 0.83 | 1.19 | |
| 1-year return as of 2026-07-22 close | +201.1% | +100.9% | ANAB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.